172@29@17@107!~!172@29@0@53!~!|news|axisniftyetf|management-interviews-AET02-6months.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
you are here: HomeNewsAxisniftyetf
management interviews
Jump to
7 Results Found
  • Not impacted by pricing pressure in pharma sector in the US: Advanced Enzymes May 29, 2017 03:23 PM IST

    Not impacted by pricing pressure in pharma sector in the US: Advanced Enzymes

    In an interview to CNBC-TV18, Piyush Rathi, Director & CMO of Advanced Enzyme Technologies spoke about the results and his outlook for the company.

  • See huge future in nutrition growth, says Advanced Enzyme Mar 23, 2017 09:19 AM IST

    See huge future in nutrition growth, says Advanced Enzyme

    CL Rathi, MD of Advanced Enzyme Technologies sees huge future for the company in nutrition growth along with animal nutrition.

  • Advanced Enzyme targets 25-30% CAGR growth Feb 14, 2017 03:41 PM IST

    Advanced Enzyme targets 25-30% CAGR growth

    In an interview to CNBC-TV18, CL Rathi, MD of Advanced Enzyme Technologies spoke about the results and his outlook for the company.

  • Advanced Enzyme acquires JC Biotech for Rs 50 crore Oct 28, 2016 03:19 PM IST

    Advanced Enzyme acquires JC Biotech for Rs 50 crore

    CL Rathi, Managing Director and Chief Executive of Advanced Enzyme, said the acquisition will be EPS-accretive for FY17 and is likely to have a positive impact for FY18.

  • Do not need money for capex over next 2-3 yrs: Advanced Enzyme Sep 16, 2016 12:16 PM IST

    Do not need money for capex over next 2-3 yrs: Advanced Enzyme

    Do not need any money for capex over next two-three years, says CL Rathi, MD of Advanced Enzyme Technologies.

  • Hopeful of double-digit growth over 10 years: Advanced Enzymes Aug 30, 2016 10:02 AM IST

    Hopeful of double-digit growth over 10 years: Advanced Enzymes

    The enzymes market in India is small and the company wants to expand in Americas, West Asia and far East, according to CL Rathi, Managing Director of Advanced Enzyme Technologies.

  • Advanced Enzymes unfazed by Novozymes stock dip, says biz strong Aug 11, 2016 12:35 PM IST

    Advanced Enzymes unfazed by Novozymes stock dip, says biz strong

    Speaking to CNBC-TV18, CL Rathi, MD of Advanced Enzymes (AETL) said its misguiding to compare its business with Novozymes. While AETL gets 75 percent of its business from nutrition segment, Novozymes has higher exposure to industrials where input costs are causing pressures.

Sections